Phase 3 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are over 18 years old.
- People with a life expectancy of more than 12 weeks.
- People who are not currently using opioid pain medicines, or whose daily opioid use is below a low threshold (less than 60 mg per day in oral morphine equivalent terms) (confirm with trial site).
- People with nerve damage from chemotherapy (CIPN) that has been graded as more than mild in severity (confirm with trial site).
- People experiencing nerve pain related to chemotherapy-induced nerve damage that rates above 3 out of 10 on average, and has lasted for 3 months or more after chemotherapy ended.
- People who have been diagnosed with cancer.
- People who were treated with one of these specific chemotherapy types: platinums, taxanes, vinca alkaloids, bortezomib, or thalidomide.
Who may not be able to join:
- People whose nerve damage is caused by something other than chemotherapy.
- People with certain mental health conditions, including severe depression, suicidal thoughts, bipolar disorder, psychotic disorders, alcohol or substance use disorders, or an eating disorder as defined by DSM-5 criteria.
- People with certain serious medical conditions, including bowel blockages or conditions affecting how the bowel works, severe or uncontrolled asthma, chronic obstructive pulmonary disease (COPD), serious breathing problems, certain heart or lung conditions, seizure disorders, serious brain or spinal pressure conditions, certain types of diarrhoea, or a condition called leptomeningeal disease.
- People with significant liver or kidney problems identified within the last 90 days, based on specific medical test results (confirm with trial site).
- People with a specific type of heart rhythm abnormality (a QTc interval above 499ms) identified within the last 90 days.
- People who are currently pregnant or breastfeeding.
- People who are unable to swallow or take oral (by mouth) medications.
- People who screen positively on certain questionnaires related to alcohol use or opioid risk (confirm with trial site).
- People with a known allergy or sensitivity to opioids, duloxetine, or ingredients in their formulations.
- People currently taking certain medications that cannot be combined with the trial treatments, including methadone, most antidepressants (including within 14 days of stopping a type called MAOIs), thioridazine, or certain antibiotics or other medicines that affect how the body processes drugs.
- People with uncontrolled narrow-angle glaucoma (a specific type of eye pressure condition).
- Women who could become pregnant and are unable or unwilling to use an approved and highly effective form of contraception (or abstinence) during the trial period.
Note: People who are already taking other pain-relief medicines may be able to continue them, as long as those medicines have been at a stable dose for more than two weeks. Starting new pain medicines or changing doses of current ones will not be permitted during the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Efficacy of methadone compared to duloxetine to reduce the reported average pain intensity using the Brief Pain Inventory-Short Form questionnaire.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.